Abbreviated regulatory approval pathways for biosimilars were created to accommodate intellectual property protection, foster competition and lower drug prices, but their success in achieving these goals has been mixed.

中文翻译：

---

定性研究生物仿制药生产商和监管机构对知识产权的看法和简化的批准途径

创建了生物仿制药的简化监管批准途径以适应知识产权保护，促进竞争和降低药品价格，但是它们在实现这些目标方面的成功参差不齐。